Gastrointestinal and hepatic diseases during the COVID-19 pandemic: Manifestations, mechanism and management

Table 6 Recommendations of the American Association for the Study of Liver Diseases and European Association for the Study of the Liver for the management of auto-immune hepatitis during coronavirus disease 2019

	Selected recommendations
Virtual platforms are recommended to minimize in-person visits as much as possible
COVID-19 testing is advised in cases of acute deterioration and liver failure
Patients with low risk of complications (patients on chronic immunosuppressive therapy)	(1) Frequent patient-provider communications should be closely supervised; (2) Virtual platforms should be used to decrease contact; and (3) Ensure enough drug supply and refills to decrease running out of medications
Patients with moderate risk of complications (symptomatic disease without cirrhosis)	(1) Empiric therapy via virtual healthcare platforms as much as possible; and (2) Preventing liver biopsy whenever possible
Patients with high risk of complications (acute flare, decompensated cirrhosis)	(1) Reduce invasive procedures as much as possible; (2) In the case of COVID-19 patients, if lymphopenia develops, dose reduction of antimetabolites is recommended; and (3) In the case of infection, corticosteroids should be attenuated

COVID-19: Coronavirus disease 2019.